Aptamer selection and aptasensor construction for bone density biomarkers

Chinnappan, Raja; Zaghloul, Norhan Sameh; AlZabn, Razan; Malkawi, Abeer; Rahman, Anas M. Abdel; Abu‐Salah, Khalid M.; Zourob, Mohammed

doi:10.1016/j.talanta.2020.121818

Cited by 16 publications

(7 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The electrodes were rinsed with DI water to remove the excess aptamers and, finally, incubated with 0.5% of BSA to ensure specific binding. Due to this blocking step, the recorded signal can be ascribed only to the interaction between aptamers and the analyte [ 47 ]. Finally, the electrodes were rinsed with DI water and kept in the refrigerator at 4 °C when not in use.…”

Section: Methodsmentioning

confidence: 99%

An Aptasensor Based on a Flexible Screen-Printed Silver Electrode for the Rapid Detection of Chlorpyrifos

Inam

Angeli

Douaki

et al. 2022

Sensors

View full text Add to dashboard Cite

In this work, we propose a novel disposable flexible and screen-printed electrochemical aptamer-based sensor (aptasensor) for the rapid detection of chlorpyrifos (CPF). To optimize the process, various characterization procedures were employed, including Fourier transform infrared spectroscopy (FT-IR), electrochemical impedance spectroscopy (EIS), and cyclic voltammetry (CV). Initially, the aptasensor was optimized in terms of electrolyte pH, aptamer concentration, and incubation time for chlorpyrifos. Under optimal conditions, the aptasensor showed a wide linear range from 1 to 105 ng/mL with a calculated limit of detection as low as 0.097 ng/mL and sensitivity of 600.9 µA/ng. Additionally, the selectivity of the aptasensor was assessed by identifying any interference from other pesticides, which were found to be negligible (with a maximum standard deviation of 0.31 mA). Further, the stability of the sample was assessed over time, where the reported device showed high stability over a period of two weeks at 4 °C. As the last step, the ability of the aptasensor to detect chlorpyrifos in actual samples was evaluated by testing it on banana and grape extracts. As a result, the device demonstrated sufficient recovery rates, which indicate that it can find application in the food industry.

show abstract

Section: Methodsmentioning

confidence: 99%

An Aptasensor Based on a Flexible Screen-Printed Silver Electrode for the Rapid Detection of Chlorpyrifos

Inam

Angeli

Douaki

et al. 2022

Sensors

View full text Add to dashboard Cite

show abstract

“…It has been widely used to recognize various targeted sites, such as small molecules of antibiotics, short peptides, metal ions, and organic dyes, as well as a wide variety of proteins with complex multimeric structures, also including cells, viruses, and bacteria ( Wang et al, 2015 ). Aptamers have been used for diagnosis, detection, and targeted therapy due to their easy acquisition and great targeting ability ( Chinnappan et al, 2021 ). In addition, the high stability of aptamers, their low toxicity and immunogenicity, and their chemical modification to confer controlled or periodic denaturation and renaturation have expanded the flexibility of aptamer use in various biomaterials ( Ye et al, 2012 ).…”

Section: Bone-targeted Strategiesmentioning

confidence: 99%

Bone-Targeted Nanoparticle Drug Delivery System: An Emerging Strategy for Bone-Related Disease

Chen

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Targeted delivery by either systemic or local targeting of therapeutics to the bone is an attractive treatment for various bone metabolism diseases such as osteoporosis, osteoarthritis, osteosarcoma, osteomyelitis, etc. To overcome the limitations of direct drug delivery, the combination of bone-targeted agents with nanotechnology has the opportunity to provide a more effective therapeutic approach, where engineered nanoparticles cause the drug to accumulate in the bone, thereby improving efficacy and minimizing side effects. Here, we summarize the current advances in systemic or local bone-targeting approaches and nanosystem applications in bone diseases, which may provide new insights into nanocarrier-delivered drugs for the targeted treatment of bone diseases. We envision that novel drug delivery carriers developed based on nanotechnology will be a potential vehicle for the treatment of currently incurable bone diseases and are expected to be translated into clinical applications.

show abstract

“…Aptamers can bind to highly toxic or non-immunogenic antigens, an attribute that cannot be achieved with animal-based methods of mAb production. Aptamers are intermediate in size (8)(9)(10)(11)(12)(13)(14)(15)) between antibodies (150 kDa) and small peptides (1-5 kDa), and about 20 times smaller than antibodies [3]. Their small size can lead to better tissue penetration, which can be used in solid tumor therapy.…”

Section: Monoclonal Antibodies Aptamersmentioning

confidence: 99%

“…During the SELEX process, the target molecules are immobilized on a solid support (e.g., chromatographic beads or sepharose beads) to facilitate the separation of targetbinding oligonucleotides from non-binding ones. The ssDNA library pool of 10 15 random nucleotide sequences are incubated with immobilized target molecule and the enrichment in the ssDNA binding aptamer is monitored by the fluorescence [9]. SELEX can be performed against the purified protein as well as against whole cells by cell-SELEX, and the ssDNA/RNA aptamers bind to specific cell membrane proteins existing on live cells.…”

Section: Aptamer Selection Technologymentioning

confidence: 99%

Aptamers: Potential Diagnostic and Therapeutic Agents for Blood Diseases

et al. 2022

Self Cite

View full text Add to dashboard Cite

Aptamers are RNA/DNA oligonucleotide molecules that specifically bind to a targeted complementary molecule. As potential recognition elements with promising diagnostic and therapeutic applications, aptamers, such as monoclonal antibodies, could provide many treatment and diagnostic options for blood diseases. Aptamers present several superior features over antibodies, including a simple in vitro selection and production, ease of modification and conjugation, high stability, and low immunogenicity. Emerging as promising alternatives to antibodies, aptamers could overcome the present limitations of monoclonal antibody therapy to provide novel diagnostic, therapeutic, and preventive treatments for blood diseases. Researchers in several biomedical areas, such as biomarker detection, diagnosis, imaging, and targeted therapy, have widely investigated aptamers, and several aptamers have been developed over the past two decades. One of these is the pegaptanib sodium injection, an aptamer-based therapeutic that functions as an anti-angiogenic medicine, and it is the first aptamer approved by the U.S. Food and Drug Administration (FDA) for therapeutic use. Several other aptamers are now in clinical trials. In this review, we highlight the current state of aptamers in the clinical trial program and introduce some promising aptamers currently in pre-clinical development for blood diseases.

show abstract

Aptamer selection and aptasensor construction for bone density biomarkers

Cited by 16 publications

References 41 publications

An Aptasensor Based on a Flexible Screen-Printed Silver Electrode for the Rapid Detection of Chlorpyrifos

An Aptasensor Based on a Flexible Screen-Printed Silver Electrode for the Rapid Detection of Chlorpyrifos

Bone-Targeted Nanoparticle Drug Delivery System: An Emerging Strategy for Bone-Related Disease

Aptamers: Potential Diagnostic and Therapeutic Agents for Blood Diseases

Contact Info

Product

Resources

About